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In addition to the direct targeting effects on HER2-positive cells, trastuzumab may have a therapeutic role modulating the activity of
the cellular immune system in patients with breast cancer. To investigate this further, the balance of T-regulatory (Treg), Th17, natural
killer (NK) and NK T (NKT) cells before, during and after trastuzumab therapy was investigated. Sequential frequencies of circulating
Treg cells, Th17 cells, NK and NKT cells were measured in peripheral blood of breast cancer patients and normal controls throughout
therapy. Individuals with breast cancer had significantly higher Treg frequencies of peripheral blood compared with healthy controls
(9.2 or 8.6 vs 6%; Po0.05), and no significant differences in Treg frequencies were observed between HER2-positive and HER2-
negative individuals. The number of Th17 cells was lowest in HER2-positive patients compared with both healthy controls and HER2-
negative patients (0.31 vs 0.75% or 0.84%; P¼0.01). There appeared to be an inverse relationship between Treg and Th17
frequencies in metastatic breast cancer (MBC) with Treg levels significantly reduced during treatment with trastuzumab (P¼0.04),
whereas Th17 frequencies were concomitantly increased (P¼0.04). This study supports earlier data that Treg cells are present at
higher frequencies in breast cancer patients compared with healthy individuals. For the first time, we show that HER2-positive
individuals with breast carcinomas have reduced numbers of circulating Th17 cells, which appear, in turn to have an inverse
relationship with Treg frequency in MBC. The change in balance of the Treg:Th17 ratio appears to characterise the cancer state, and
furthermore, is disrupted by trastuzumab therapy.
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Several studies have shown that higher numbers of T-regulatory
(Treg) cells are associated with progression in a variety of
malignancies, and Treg numbers appear increased in individuals
with a variety of solid tumours (lung, breast and pancreas) and
haematological malignancies, and this is reflected in the peripheral
blood (PB) of cancer patients (Woo et al, 2001; Liyanage et al,
2002; Diederichsen et al, 2003; Javia and Rosenberg, 2003; Wolf
et al, 2003; Marshall et al, 2004; Galon et al, 2006; Nedergaard et al,
2007). The Treg subgroup of immune cells suppresses the activity
of effector cells, including CD4þ and CD8þ cytotoxic T cells,
natural killer (NK) cells, dendritic cells, NK T (NKT) cells and B
cells (Murakami et al, 2002; Trzonkowski et al, 2004). The outcome
of this activity appears to promote the survival of cancer cells by
affording protection from both the innate and adaptive immune
systems.
Th17 cells have been defined as an immune subset of CD4þ
lymphocytes, characterised by their production of the cytokines
IL6, IL17 and TNF-a and expression of the transcription
factor, RORgT. They have been implicated in inflammation
and autoimmune disease, but little is known about their
prevalence and function in human cancer. Initial reports have
identified Th17s within ovarian tumour (Kryczek et al, 2007;
Miyahara et al, 2008), but their precise role in this setting remains
unclear.
The differentiation of Th17 cells is promoted by IL-23, an
inducer of experimental autoimmune encephalitis (Langrish et al,
2005; McKenzie et al, 2006), and it is thought that TGF-b plays a
key role in determining whether CD4þ lymphocytes become Treg
or Th17 cells in vitro and possibly in vivo (Veldhoen et al, 2006;
Zhou et al, 2008). The balance of Treg cells and Th17s may
influence the immune response against cancer, with a Treg bias
favouring tumour immune escape.
There are increasing data that the activity of regulatory cells
controlling the cellular immune system may have importance in
the clinical outcomes of cancer therapies (Bamias et al, 2008).
Some chemotherapeutic agents, such as cyclophosphamide, have
been shown to lead to reduced numbers of functional Treg cells
(Beyer and Schultze, 2006). Conversely, those treated with high-
dose interleukin-2 (IL-2) for melanoma and renal cell carcinoma
show expansion of these cells (Ahmadzadeh and Rosenberg, 2006).
In breast cancer, it is unclear whether trastuzumab, an IgG1
monoclonal antibody, has direct effects on Treg immune subsets.
Revised 4 February 2009; accepted 10 February 2009; published online
10 March 2009
*Correspondence: Dr J Stebbing, Department of Medical Oncology,
Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham
Palace Road, London W6 8RF, UK; E-mail: j.stebbing@imperial.ac.uk
British Journal of Cancer (2009) 100, 1061–1067


























sSeveral studies have shown an increased prevalence of circulating
Treg cells in breast cancer patients compared with normal controls
(Liyanage et al, 2002; Perez et al, 2007), and the presence of Treg
cells is likely to correlate to cancer progression. However, the effect
of breast cancer therapies, such as trastuzumab, upon Treg cells
and other immune subsets remains unknown. Here, we have
examined the numbers of Treg cells, Th17, NK and NKT cells in
Her-2/neu (HER2)-positive (early and metastatic breast cancer
(MBC)) and HER2-negative breast cancer patients, with the aim of
further elucidation of the role of Treg and Th17 cells, and their




Between September 2007 and January 2009, patients with HER2-
positive breast cancer were recruited before therapy with
trastuzumab. Individuals with negative HER2 and healthy controls
were also recruited. The study obtained appropriate ethical
approval in accordance with the Declaration of Helsinki.
Peripheral blood was collected before and during therapy into
sodium heparin tubes, and PB mononuclear cells (PBMCs) were
isolated by density centrifugation, and frozen in liquid nitrogen
until analysis.
Patients receiving adjuvant trastuzumab had completed cyto-
toxic chemotherapy X3 weeks before the baseline blood sample,
and then went on to receive trastuzumab monotherapy. The
majority of individuals whom we studied receiving trastuzumab
for metastatic disease also received monotherapy, but a minority
were treated in combination with docetaxel or vinorelbine.
Samples were taken before the beginning of the treatment, during
the treatment (one or more time points), and for early breast
cancer (EBC) patients, samples were also taken following the
completion of the course of adjuvant trastuzumab. In addition,
samples from seven HER2-negative patients and four healthy
donors (all age-matched females) were also obtained. As we treat
patients with metastatic cancer with trastuzumab beyond progres-
sion, we did not obtain ‘metastatic samples’ post-treatment for this
study.
Cell staining
Before intracellular staining, PBMCs were thawed and restimulated
for 4h with 50ngml
 1 phorbol 12-myristate 13-acetate (PMA) and
100ngml
 1 ionomycin in the presence of (10mgml
 1) protein
transport inhibitor Brefeldin A (Sigma, Poole, UK). Cells were
surface stained with combinations of CD4-APC (clone RPA-T4),
CD3-PE (UCHT1), CD25-FITC (BC96), CD45RO-FITC (UCHL1),
CD56-FITC (MEM188), GITR-PE (ebioAITR) and CTLA-4-PE
(14D3; all antibodies from eBioscience, San Diego, CA, USA).
Cells were fixed and permeabilised with the FoxP3 fix/perm kit
(eBioscience), and intracellularly stained with PE-conjugated
antibodies against FoxP3 and IL-17A (clones PCH101 and
eBio64DEC17, respectively, from eBioscience). Isotype control
antibodies were used to determine the background fluorescence.
Flow cytometry analysis
Peripheral blood mononuclear cells were analysed on a FACSca-
libur flow cytometer equipped with CellQuest software (BD
Biosciences, San Jose, CA, USA), and data were analysed using
FlowJo v. 7 (Treestar Inc., Ashland, OR, USA). Regulatory T cells
were defined as CD4þFoxP3þCD25þ, and the expression of
GITR and CTLA were also measured. Th17 cells were defined as
CD4þIL17Aþ; NK cells were defined as CD3-CD56þ, whereas
NKT cells were counted as CD3þCD56þ cells.
Statistics
All statistical comparisons between sample groups were carried
out using the non-parametric Mann–Whitney U-test with P-values
o0.05 considered significant. For patients who died, we used the
last observation carried forward for statistical analyses.
RESULTS
Breast cancer patients have increased numbers of Treg cells
A total of 27 patients with HER2-positive breast cancer were
recruited. All of these individuals were being treated with
trastuzumab, either in the adjuvant setting for EBC (n¼14; mean
age 53 years, range: 33–64) or for MBC (n¼13; mean age 58, range
32–79). During the course of this study, two HER2-positive
patients died.
Initially, a comparison of cell frequencies between HER2-
positive and HER2-negative breast cancer patients was under-
taken. Regulatory T cells were characterised as CD4þFoxP3þ;i n
addition, the expression of CD25, GITR and CTLA-4 among this
population was also confirmed (Figure 1A). The absolute numbers
and percentage of Treg cells in the PB of healthy individuals
and breast cancer patients was determined, and our data show
that individuals with breast cancer have a significantly higher
Treg frequency in the PB compared with healthy controls;
Treg frequencies were 48% of CD4þ cells in breast cancer,
compared with 6% of CD4þ cells in healthy controls (Po0.05).
The frequency of Treg cells precisely reflected the absolute
numbers of Treg cells observed (as measured as the number
of Treg cells per million PBMCs counted; Supplementary data
figure).
To further investigate the role of HER2 status and therapy, we
divided patients into HER2-positive or HER2-negative groups. Our
data showed that patients with HER2-positive breast cancer had
significantly higher frequencies of Treg cells compared with healthy
individuals (8.4 vs 6%; P¼0.021), whereas the frequency was
similar for both HER2-positive and HER2-negative patients (8.4 vs
9.2%; P¼0.27; Figure 1B). HER2-positive patients during treat-
ment with trastuzumab had a reduced frequency of Treg cells,
compared with that seen at baseline before therapy, but this
difference was not statistically significant.
Numbers of Th17 cells are decreased in HER2-positive
breast cancer patients
As for the Treg cells, the frequency and absolute number of Th17
cells were measured and compared in healthy individuals and
HER2-positive and -negative breast cancer patients (Figure 2 and
Supplementary data). Healthy individuals and HER2-negative
breast cancer patients had similar Th17 numbers, and in an
inverse relationship than that observed in Treg cells, HER2-positive
patients had significantly lower frequencies of Th17s compared
with healthy and HER2-negative individuals (0.314% compared
with 0.748% (P¼0.014) and 0.84% (P¼0.0088), respectively). We
observed that the number of Th17 cells increased upon treatment
with trastuzumab (0.314% compared with 0.579%; not significant).
The balance of Treg and Th17 cells in PB is altered in
HER2-positive breast cancer
To further quantify the relationship between Treg and Th17
numbers in patients with breast cancer, the number of Treg cells to
every Th17 cell was calculated as a ratio. Here, we found that
HER2-positive breast cancer patients had the highest ratio of
Treg:Th17 cells (Figure 3; 35.5:1, Treg:Th17 compared with 8:1 in
healthy donors; P¼0.006); HER2-negative patients had a similar
balance of Treg:Th17 compared with healthy donors (14:1
Th17 and Treg cells during trastuzumab
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scompared with 8:1; P¼0.26). Upon treatment with trastuzumab,
the Treg:Th17 bias seen in HER2-positive individuals was reduced
slightly to 32:1.
A converse relationship between Treg and Th17 frequency
is seen in MBC
We then sought to address whether the increase of Treg cells
observed in individuals treated with trastuzumab was a ‘drug-
specific’ change dependent on cancer stage. Patients were divided
into those who had EBC with no metastatic sites, and patients who
had at least one metastatic site (MBC). This revealed individuals with
EBC had similar Treg frequencies before, and during trastuzumab
therapy (9 and 9.5%, respectively; Figure 4A), with a slight increase
following the completion of the course of treatment. The Treg
frequency in EBC was comparable to that seen in HER2-negative
cancer patients (9 vs 9.2%; P¼0.79). Metastatic breast cancer
patients had the highest frequency of Treg cells from all populations
that we studied (11.1% pre-treatment); this significantly decreased
when patients were treated with trastuzumab (7.8%; P¼0.039).
As for Treg cells, EBC patients had similar Th17 frequencies
pre-, during and post-trastuzumab therapy (0.33, 0.45 and 0.32%,
respectively). However, in MBC patients, the frequency of Th17s
in PB followed an inverse relationship to Treg cell frequency, with
numbers significantly increasing during treatment with trastuzu-
mab (0.32 vs 0.64%; P¼0.038). The frequency of Th17 cells in
HER2-negative breast cancer patients was comparable with that



































Figure 2 The number of circulatory Th17 cells is decreased in HER2þ
breast cancer patients. The frequency of Th17 cells in HER2  breast
cancer patients (grey) did not differ from that measured in healthy
individuals (black). HER2þ breast cancer patients (white) had significantly
lower Th17 frequency compared with both healthy individuals and HER2 
patients, and the frequency of Th17s increased during trastuzumab therapy.
Th17 frequency was measured as the frequency of CD4þIL17Aþ T cells
as a percentage of total CD4þ cells. Error bars represent±s.e. P-values






































Figure 3 The Treg/Th17 bias is highest in HER2þ breast cancer. The
Treg:Th17 cell ratio in healthy individuals (black), HER2  breast cancer
patients (grey) and HER2þ breast cancer patients treated with trastuzumab
(white). The number of Treg cells to Th17s is significantly higher in
HER2þ breast cancer patients compared with healthy individuals and
HER2  breast cancer patients, with a slight decrease during trastuzumab
treatment. The number of Treg cells to every Th17 cell is shown. P-values










































































Figure 1 Treg frequency is increased in breast cancer patients compared with healthy individuals. (A) A representative Treg FACS plot showing
CD4þFoxP3þ cells. By gating on the CD4þFoxP3þ cells, it was shown that they were also CD25 expressing (shown in histogram; key to histogram:
isotype control (dotted grey line), CD4þFoxP3- cells (grey line), CD4þFoxP3þ cells (black line)). (B) Comparison of Treg frequencies in healthy
individuals (black), HER2  breast cancer patients (grey) and HER2þ breast cancer patients, either before or during treatment with trastuzumab (white).
Shown is the frequency of Treg cells as a percentage of total CD4þ cells. Error bars represent±s.e. P-values o 0.05, as measured by the Mann–Whitney
U-test, were considered significant.
Th17 and Treg cells during trastuzumab
C Horlock et al
1063

























sWhen quantifying the relationship between Treg and Th17
frequency, we found that of all populations studied, healthy
individuals had the lowest number of Treg cells to every Th17 cell
(8.6:1). This was significantly lower than that seen in HER2-
negative breast cancer (16:1; P¼0.046), HER2-positive EBC
patients (30:1; P¼0.017) and also HER2-positive MBC patients
(40:1; P¼0.014). In EBC, the Treg:Th17 frequency increased
during treatment with trastuzumab, then decreased slightly
following completion, but not quite to the levels seen before
treatment (pre-treatment: 30:1, during: 41.4:1, post-treatment:
37.1:1). In MBC, however, the Treg:Th17 ratio decreased during
treatment (40:1 vs 26.8:1; P¼0.031; Figure 5).
As samples were obtained at multiple time points over the
course of trastuzumab treatment, the frequency of cells over
time was also measured. The majority of patients remained on the
same treatment regime throughout the period of this study, and
the frequency of cells (all subsets) remained consistent throughout
the specific treatment time course and changed only on starting or
stopping the trastuzumab.
Natural killer and NKT cells in breast cancer
In addition to Treg and Th17 cells, the absolute numbers of









































































































































































Figure 4 The effect of breast cancer stage and trastuzumab on Treg and Th17 frequencies. The frequency of Treg cells and Th17s was measured pre-
(white), during (grey) and post (black)-trastuzumab therapy in early breast cancer (EBC) and metastatic breast cancer (MBC) patients. The third histogram
shows the relative frequencies seen in healthy and HER2  controls. (A)T reg cells (B) Th17s. Trastuzumab therapy in MBC leads to a statistically significant
decrease in the frequency of Treg cells, and conversely, a statistically significant increase in Th17s. Error bars represent±s.e. P-values o 0.05, as measured by
the Mann–Whitney U-test, were considered significant.
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ssignificant difference between patient populations. The balances
and frequencies of NK:NKT cells and Treg:NKT cells were also
investigated (as others have performed in inflammatory settings),
but again no significant differences were observed.
DISCUSSION
This study is one of the first to document circulating Th17 cells in
human cancer patients. Th17 cells have been found in the human
gut and PB, and are thought to play a role in inflammatory and
autoimmune disorders (Stockinger and Veldhoen, 2007); but their
role in cancer, especially in vivo, is however unknown.
We have shown that HER2-positive breast cancer patients have
significantly lower frequencies of Th17 cells in their PB compared
with both healthy individuals and HER2-negative breast cancer
patients. This contradicts a recent study that suggested that
although the tumour environment in ovarian cancer was
favourable for generation of Th17 cells, the frequencies of Th17
cells in the PB of cancer patients was comparable to that seen in
healthy individuals (Miyahara et al, 2008). In addition, we showed
that in breast cancer, circulating Treg cells are increased compared
with healthy controls (data supported by earlier study (Wolf et al,
2003)). We also observed that although HER2-positive breast
cancer patients have a significantly higher frequency of Treg cells
compared with healthy donors; the frequency of Treg cells in
HER2-positive and -negative individuals did not differ. This
finding is in contrast with the data of Perez et al (2007) who found
that HER2-negative patients had similar frequencies of Treg cells as
healthy donors, but that HER2-positive individuals had signifi-
cantly higher proportions than both populations.
It is clear that the development of Treg and Th17 cells is closely
linked, and both require TGF-b for their differentiation from naı ¨ve
T cells (Ivanov et al, 2006; Davidson et al, 2007). Recently, the
balance of Treg and Th17 cells, and the regulatory balance between
these cell types has been of interest to several groups (Elias et al,
2008; Quintana et al, 2008; Veldhoen et al, 2008; Zhou et al, 2008).
Although both cell types require TGF-b, other compounds, such as
IL-6 and retinoic acid (Nishihara et al, 2007; Wan et al, 2007; Elias
et al, 2008), specifically promote either Treg or Th17 cells while
suppressing the other cell type.
To further quantify this relationship, we examined the balance
between Treg and Th17 cells, by calculating the ratio of Treg:Th17
cells. It was shown that HER2-positive patients had a much higher
Treg:Th17 ratio than both HER2-negative individuals and healthy
controls. The Treg:Th17 ratio was significantly reduced in MBC
patients during trastuzumab therapy, but no such relationship was
observed in EBC patients treated with adjuvant trastuzumab. In
addition to the Treg:Th17 axis, a regulatory relationship between
Treg and NKT cells has also been described (La Cava et al, 2006); the
relationship between these cells in the context of breast cancer was
therefore examined. We showed no significant differences in NKT
cell numbers between all populations, and no significant difference
in the Treg:NKT ratio. This suggests that the Treg:Th17 balance ratio
is of greater importance than that of the Treg:NKT in breast cancer.
Increasing evidence suggests that the activity of regulatory cells
controlling the cellular immune system may have importance in the
clinical outcomes of cancer therapies (Bamias et al, 2008). Several
studies have shown that higher numbers of Treg cells are associated
with progression in a variety of malignancies and can correlate to
the poor prognosis (Liyanage et al, 2002; Galon et al, 2006). Here,
we suggest that trastuzumab treatment in MBC affects both the
numbers of Treg cells and the frequency of circulating Th17 cells.
Most patients in this study were receiving trastuzumab
monotherapy; however, a small proportion received trastuzumab
in combination with docetaxel or vinorelbine. Although we did not
directly address the effect of chemotherapeutic agents alone on
Treg and Th17 frequencies, we observed no significant differences
between the patient population treated with monotherapy and
those treated in combination with chemotherapy. Accordingly,
Perez et al (2007) noted no specific difference in Treg frequencies in
HER2-negative breast cancer patients receiving the same chemo-
therapy regimen as patients receiving trastuzumab in combination,













































































Figure 5 The Treg/Th17 balance. The ratio of Treg:Th17 cells was measured pre- (white), during (grey), and post (black)-trastuzumab therapy in early
breast cancer (EBC) and metastatic breast cancer (MBC) patients. The third histogram shows the relative ratios seen in healthy and HER2  controls. The
number of Treg cells to every Th17 cell is shown. Error bars represent ±s.e. P-values o0.05, as measured by the Mann–Whitney U-test, were considered
significant.
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sattributed specifically to trastuzumab therapy. Samples were taken
from participating patients throughout their treatment, and for
most patients, the immune populations measured were similar
throughout the period of trastuzumab therapy.
Here, we saw a reduction of Treg numbers, coupled with a
converse increase of Th17 cells in the PB of MBC patients receiving
trastuzumab therapy. This effect was less pronounced in the
adjuvant setting for reasons that remain unclear. Measurement of
the frequency of immune cells, such Treg and Th17 cells may prove
useful in identifying whether patients are showing any positive
response to treatment or not, and this would enable cessation of
unnescessary therapy in unresponsive patients. This would be
beneficial as trastuzumab is both expensive and can sometimes be
associated with serious side effects including cardiotoxicity (Mariani
et al, 2008). Whether direct HER2 targeting or an antibody affect is
involved in the change in number of Treg and Th17 cells in
trastuzumab-treated HER2-positive breast cancer remains unclear.
It is possible that trastuzumab may lead to the changes in the
cytokine milieu or other factors that may drive expansion of Th17
cells and/or prevent the survival of Treg cells in the body.
This study has been limited by small sample sizes, and functional
data have not been collected. Our results, however, support the role
of Treg and Th17 cells in trastuzumab therapy. It would appear that
further studies are required to confirm the relationship between
Treg frequencies and cancer as some of our data conflict with those
published previously (Perez et al, 2007). In addition, it may be of
interest to further study the effect of trastuzumab therapy in EBC
with more patients. It would be of particular interest to observe
whether the efficacy of adjuvant therapy in HER2-positive EBC
patients could be ultimately predicted by studying the frequency
and functionality of patients’ Treg and Th17 cells.
These data are of interest in cancer therapy in general, as
harnessing the immune system to improve responses to existing
therapies is of increasing importance in clinical trial design of
newer immunotherapeutics. The coadministration of trastuzumab
along with therapies that either promote Th17 or reduce Treg cells
may be a particular direction, with the aim of ultimately improving
the prognosis for patients unresponsive to trastuzumab or other
therapies.
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